Open AccessRisk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
Author(s) -
Andrew Booth,
Ashley M. Hopkins,
Andrew Rowland,
Ganessan Kichenadasse,
Justine R. Smith,
Michael J. Sorich
Publication year - 2020
Publication title -
therapeutic advances in medical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.272
H-Index - 49
eISSN - 1758-8359
pISSN - 1758-8340
DOI - 10.1177/1758835920944359
Subject(s) - medicine , vemurafenib , retinopathy , odds ratio , mek inhibitor , adverse effect , gastroenterology , oncology , surgery , dermatology , diabetes mellitus , endocrinology , cancer , mapk/erk pathway , microbiology and biotechnology , kinase , metastatic melanoma , biology
Age, glomerular filtration rate and history of ocular disease (particularly inflammatory eye disease) were associated with a risk of MEK inhibitor induced retinopathy. Patients who are at increased risk of MEKAR may benefit from more regular ophthalmologic assessment during treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom